Virax Biolabs announces 1-for-25 share consolidation
The consolidation aims to regain Nasdaq compliance and will be effective June 26, 2026.
See the latest news and media coverage for Virax Biolabs. We track all announcements, press releases, and industry mentions in real time, all in one place.
Immunology research company
viraxbiolabs.comLast updated
In short: Virax Biolabs announced a 1-for-25 share consolidation to regain Nasdaq compliance while advancing its immune profiling diagnostic tests.
The consolidation aims to regain Nasdaq compliance and will be effective June 26, 2026.
It is developing a peptide pool for the Bundibugyo strain and offers one for the Zaire strain.
The certifications support regulated IVD development and U.S. clinical validation for its PAIS strategy.
The offering of 12.5M shares at $0.40 each will provide working capital. H.C. Wainwright acted as placement agent.
Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that the board of directors of the Company approved a share consolidation of...
Detailed price information for Virax Biolabs Group Limited (VRAX-Q) from The Globe and Mail including charting and trades.
Virax Biolabs Group Limited VRAX shares are trending on Tuesday. VRAX shares rose 17.36% to $0.28 in after-hours trading on Monday. The jump in the...
Detailed price information for Virax Biolabs Group Limited (VRAX-Q) from The Globe and Mail including charting and trades.
Track Virax Biolabs and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Virax Biolabs and other trending companies.